NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA […]